Behind On COVID, This Immunology Stock’s Real Value Could Come From Another Product In Its Pipeline

Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product candidate in its pipeline which has shown early promise as a treatment for chronic hepatitis B virus infection. For more, CLICK HERE.